Skip to main content
Top
Published in: Diabetology International 1/2022

01-01-2022 | Insulins | Case Report

Non-autoimmune acute-onset type 1 diabetes mellitus newly developed in an elderly patient presenting elevation of serum pancreatic exocrine enzymes

Authors: Akinori Kanzaki, Morihiro Matsuda, Shinji Yokota, Kenji Takai, Jun Murai, Akihito Otsuka, Hidenori Koyama, Tadashi Nakamura

Published in: Diabetology International | Issue 1/2022

Login to get access

Abstract

An 82 year-old female patient not suffering from diabetes was transported to our hospital with hyperglycemia (HbA1c 8.2%, blood glucose 584 mg/dL) and mildly increased levels of pancreatic exocrine enzymes (amylase 543 IU/L, lipase 59 U/L, elastase-1 479 ng/dL), while there were no findings indicating pancreatitis. Under a diagnosis of new-onset diabetes, she was discharged with oral hypoglycemic agents, as retention of insulin secretion function [blood glucose 117 mg/dL, serum connecting peptide immunoreactivity (CPR) 1.63 ng/mL] with normalization of the enzymes was confirmed following administration. However, at 73 days after the hospitalization, she returned with diabetic ketoacidosis (blood glucose 910 mg/dL, pH in blood gas analysis 7.15, total blood ketone bodies > 7000 µmol/L) with a transient repeated increase of the enzymes (amylase 382 IU/L, lipase 82 U/L, elastase-1 569 ng/dL) and without pancreatitis. Notably, depletion of insulin secretion (6.1 µg/day in urine, 0.36 ng/mL in serum CPR with no response in glucagon-loading test) was revealed, and serum CPR level remained low after discharge. Together with negative findings for islet-related autoantibodies, the patient was diagnosed with acute-onset type 1B diabetes (T1BD). In the present patient with acute-onset T1BD, a mild increase in pancreatic exocrine enzymes was repeatedly observed, which may mimic fulminant type and raise questions for us about the commonly accepted pathophysiology of T1D. These findings may help to clarify issues related to newly developed T1D in elderly individuals.
Literature
1.
go back to reference Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM study group. N Engl J Med. 2000;342:301–7.CrossRef Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM study group. N Engl J Med. 2000;342:301–7.CrossRef
2.
go back to reference Kawasaki E, Maruyama T, Imagawa A, Awata T, Ikegami H, Uchigata Y, et al. Diagnostic criteria for acute-onset type 1 diabetes mellitus (2012): report of the committee of Japan diabetes society on the research of fulminant and acute-onset type 1 diabetes mellitus. J Diabetes Investig. 2014;5:115–8.CrossRef Kawasaki E, Maruyama T, Imagawa A, Awata T, Ikegami H, Uchigata Y, et al. Diagnostic criteria for acute-onset type 1 diabetes mellitus (2012): report of the committee of Japan diabetes society on the research of fulminant and acute-onset type 1 diabetes mellitus. J Diabetes Investig. 2014;5:115–8.CrossRef
3.
go back to reference Delong T, Wiles TA, Baker RL, Bradley B, Barbour G, Reisdorph R, et al. Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion. Science. 2016;351:711–4.CrossRef Delong T, Wiles TA, Baker RL, Bradley B, Barbour G, Reisdorph R, et al. Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion. Science. 2016;351:711–4.CrossRef
4.
go back to reference Kracht MJL, van Lummel M, Nikolic T, Joosten AM, Laban S, van der Slik AR, et al. Autoimmunity against a defective ribosomal insulin gene product in type 1 diabetes. Nat Med. 2017;23:501–7.CrossRef Kracht MJL, van Lummel M, Nikolic T, Joosten AM, Laban S, van der Slik AR, et al. Autoimmunity against a defective ribosomal insulin gene product in type 1 diabetes. Nat Med. 2017;23:501–7.CrossRef
5.
go back to reference Kaneko K, Satake C, Yamamoto J, Takahashi H, Sawada H, Imai J, et al. A case of idiopathic type 1 diabetes with subsequent recovery of endogenous insulin secretion despite initial diagnosis of fulminant type 1 diabetes. Endocr J. 2017;64:369–74.CrossRef Kaneko K, Satake C, Yamamoto J, Takahashi H, Sawada H, Imai J, et al. A case of idiopathic type 1 diabetes with subsequent recovery of endogenous insulin secretion despite initial diagnosis of fulminant type 1 diabetes. Endocr J. 2017;64:369–74.CrossRef
6.
go back to reference Tamura Y, Araki A, Chiba Y, Ishimaru Y, Ishimaru Y, Horiuchi T, et al. A case of type 2 diabetes mellitus in an elderly patient with rapid attenuation of insulin secretion that resembled fulminant type 1 DM but with incomplete beta cell damage. Endocr J. 2006;53:633–7.CrossRef Tamura Y, Araki A, Chiba Y, Ishimaru Y, Ishimaru Y, Horiuchi T, et al. A case of type 2 diabetes mellitus in an elderly patient with rapid attenuation of insulin secretion that resembled fulminant type 1 DM but with incomplete beta cell damage. Endocr J. 2006;53:633–7.CrossRef
7.
go back to reference Makino S, Hamada S, Iwata M, Fujiwara M. A case of abrupt onset autoimmune type 1 diabetes mimicking fulminant type 1 diabetes. Endocr J. 2009;56:1113–7.CrossRef Makino S, Hamada S, Iwata M, Fujiwara M. A case of abrupt onset autoimmune type 1 diabetes mimicking fulminant type 1 diabetes. Endocr J. 2009;56:1113–7.CrossRef
8.
go back to reference Katsumata K, Katsumata K. A Chinese patient presenting with clinical signs of fulminant type 1 diabetes mellitus. Intern Med. 2005;44:967–9.CrossRef Katsumata K, Katsumata K. A Chinese patient presenting with clinical signs of fulminant type 1 diabetes mellitus. Intern Med. 2005;44:967–9.CrossRef
9.
go back to reference Iwaoka T. A case of fulminant type 1 diabetes with transiently positive anti-GAD antibodies. Endocr J. 2003;50:225–31.CrossRef Iwaoka T. A case of fulminant type 1 diabetes with transiently positive anti-GAD antibodies. Endocr J. 2003;50:225–31.CrossRef
10.
go back to reference Oikawa Y, Shimada A. Possible involvement of autoimmunity in fulminant type 1 diabetes. Diabetol Int. 2020;11:329–35.CrossRef Oikawa Y, Shimada A. Possible involvement of autoimmunity in fulminant type 1 diabetes. Diabetol Int. 2020;11:329–35.CrossRef
11.
go back to reference Hanahusa T, Imagawa A, Iwahashi H, Uchigata Y, Kanastuka A, Kawasaki E, et al. Report of Japan diabetes society committee on fulminant type 1 diabetes mellitus research: epidemiological and clinical analysis and proposal of diagnostic criteria. J Jpn Diabetes Soc. 2005;48(supplement 1):A1-13. Hanahusa T, Imagawa A, Iwahashi H, Uchigata Y, Kanastuka A, Kawasaki E, et al. Report of Japan diabetes society committee on fulminant type 1 diabetes mellitus research: epidemiological and clinical analysis and proposal of diagnostic criteria. J Jpn Diabetes Soc. 2005;48(supplement 1):A1-13.
12.
go back to reference Tsuji H. A very elderly case of acute-onset autoimmune type 1 diabetes mellitus. Nippon Ronen Igakkai Zasshi. 2010;47:622–6.CrossRef Tsuji H. A very elderly case of acute-onset autoimmune type 1 diabetes mellitus. Nippon Ronen Igakkai Zasshi. 2010;47:622–6.CrossRef
13.
go back to reference Chiba Y, Ynie J, Kimbara Y, Tamura Y, Mori S, Ito H, et al. A case of elderly-onset type1 diabetes mellitus: negative for antiglutamic acid dehydrogenase antibody and positive insulinoma-associated tyrosine phosphatase-like protein-2 antibody. Nippon Ronen Igakkai Zasshi. 2013;50:404–8.CrossRef Chiba Y, Ynie J, Kimbara Y, Tamura Y, Mori S, Ito H, et al. A case of elderly-onset type1 diabetes mellitus: negative for antiglutamic acid dehydrogenase antibody and positive insulinoma-associated tyrosine phosphatase-like protein-2 antibody. Nippon Ronen Igakkai Zasshi. 2013;50:404–8.CrossRef
14.
go back to reference Yamaguchi H, Kanadani T, Ohno M, Shirakami A. An ultra-elderly case of acute-onset autoimmune type 1 diabetes mellitus. J Endocrinol Metab. 2016;6:71–4.CrossRef Yamaguchi H, Kanadani T, Ohno M, Shirakami A. An ultra-elderly case of acute-onset autoimmune type 1 diabetes mellitus. J Endocrinol Metab. 2016;6:71–4.CrossRef
15.
go back to reference Araki E, Goto A, Kondo T, Noda M, Noto H, Origasa H, et al. Japanese clinical practice guideline for diabetes 2019. Diabetol Int. 2020;11:165–223.CrossRef Araki E, Goto A, Kondo T, Noda M, Noto H, Origasa H, et al. Japanese clinical practice guideline for diabetes 2019. Diabetol Int. 2020;11:165–223.CrossRef
16.
go back to reference Hosokawa Y, Hanafusa T, Imagawa A. Pathogenesis of fulminant type 1 diabetes: 283 genes, viruses and the immune mechanism, and usefulness of patient—derived 284 induced pluripotent stem cells for future research. J Diabetes Investig. 2019;285(10):1158–64.CrossRef Hosokawa Y, Hanafusa T, Imagawa A. Pathogenesis of fulminant type 1 diabetes: 283 genes, viruses and the immune mechanism, and usefulness of patient—derived 284 induced pluripotent stem cells for future research. J Diabetes Investig. 2019;285(10):1158–64.CrossRef
17.
go back to reference Umpierrez GE, Smiley D, Kitabchi AE. Narrative review: ketosis-prone type 2 diabetes mellitus. Ann Intern Med. 2006;144:350–7.CrossRef Umpierrez GE, Smiley D, Kitabchi AE. Narrative review: ketosis-prone type 2 diabetes mellitus. Ann Intern Med. 2006;144:350–7.CrossRef
18.
go back to reference Wilkin TJ. The accelerator hypothesis: weight gain as the missing link between type I and type II diabetes. Diabetologia. 2001;44:914–22.CrossRef Wilkin TJ. The accelerator hypothesis: weight gain as the missing link between type I and type II diabetes. Diabetologia. 2001;44:914–22.CrossRef
19.
go back to reference Mine K, Yoshikai Y, Takahashi H, Mori H, Anzai K, Nagafuchi S. Genetic susceptibility of the host in virus-induced diabetes. Microorganisms. 2020;8:1133.CrossRef Mine K, Yoshikai Y, Takahashi H, Mori H, Anzai K, Nagafuchi S. Genetic susceptibility of the host in virus-induced diabetes. Microorganisms. 2020;8:1133.CrossRef
20.
go back to reference Nishida W, Hasebe S, Kawamura R, Hashiramoto M, Onuma H, Osawa H, et al. A case of fulminant type 1 diabetes associated with high titer of coxsackie B3 virus antibody. J Jpn Diabetes Soc. 2005;48(suppl):A23–7. Nishida W, Hasebe S, Kawamura R, Hashiramoto M, Onuma H, Osawa H, et al. A case of fulminant type 1 diabetes associated with high titer of coxsackie B3 virus antibody. J Jpn Diabetes Soc. 2005;48(suppl):A23–7.
21.
go back to reference Hanafusa T, Imagawa A, Iwahashi H, Uchigata Y, Kanatsuka A, Kawasaki E, et al. Report of the Japan diabetes society’s committee on research on fulminant type 1 diabetes mellitus: analysis of antiviral antibodies at disease onset. J Jpn Diabetes Soc. 2008;51:531–6. Hanafusa T, Imagawa A, Iwahashi H, Uchigata Y, Kanatsuka A, Kawasaki E, et al. Report of the Japan diabetes society’s committee on research on fulminant type 1 diabetes mellitus: analysis of antiviral antibodies at disease onset. J Jpn Diabetes Soc. 2008;51:531–6.
22.
go back to reference Roivainen M, Knip M, Hyöty H, Kulmala P, Hiltunen M, Vähäsalo P, et al. Several different enterovirus serotypes can be associated with prediabetic autoimmune episodes and onset of overt IDDM. Childhood Diabetes in Finland (DiMe) Study Group. J Med Virol. 1998;56:74–8.CrossRef Roivainen M, Knip M, Hyöty H, Kulmala P, Hiltunen M, Vähäsalo P, et al. Several different enterovirus serotypes can be associated with prediabetic autoimmune episodes and onset of overt IDDM. Childhood Diabetes in Finland (DiMe) Study Group. J Med Virol. 1998;56:74–8.CrossRef
23.
go back to reference Kaufman DL, Clare-Salzler M, Tian J, Forsthuber T, Ting GS, Robinson P, et al. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature. 1993;366:69–72.CrossRef Kaufman DL, Clare-Salzler M, Tian J, Forsthuber T, Ting GS, Robinson P, et al. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature. 1993;366:69–72.CrossRef
24.
go back to reference Lozovskaia LS, Lavrova IK, Svetlyshev SD, Desiatskova RG, Smirnov VV. Antibodies to viruses in children with diabetes mellitus. Vopr Virusol. 1983;28:103–8.PubMed Lozovskaia LS, Lavrova IK, Svetlyshev SD, Desiatskova RG, Smirnov VV. Antibodies to viruses in children with diabetes mellitus. Vopr Virusol. 1983;28:103–8.PubMed
25.
go back to reference Kawabata Y, Ikegami H, Awata T, Imagawa A, Maruyama T, Kawasaki E, et al. Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset. Diabetologia. 2009;52:2513–21.CrossRef Kawabata Y, Ikegami H, Awata T, Imagawa A, Maruyama T, Kawasaki E, et al. Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset. Diabetologia. 2009;52:2513–21.CrossRef
26.
go back to reference Tsutsumi C, Imagawa A, Ikegami H, Makino H, Kobayashi T, Hanafusa T. Class II HLA genotype in fulminant type 1 diabetes: a nationwide survey with reference to glutamic acid decarboxylase antibodies. J Diabetes Investig. 2012;3:62–9.CrossRef Tsutsumi C, Imagawa A, Ikegami H, Makino H, Kobayashi T, Hanafusa T. Class II HLA genotype in fulminant type 1 diabetes: a nationwide survey with reference to glutamic acid decarboxylase antibodies. J Diabetes Investig. 2012;3:62–9.CrossRef
27.
go back to reference Sankoda A, Takahashi K, Matsuoka T. Clinical characteristics of patients aged 65 and older with newly developed type 1 diabetes: an analysis of elderly patients at our hospital. Nippon Ronen Igakkai Zasshi. 2016;53:143–51.CrossRef Sankoda A, Takahashi K, Matsuoka T. Clinical characteristics of patients aged 65 and older with newly developed type 1 diabetes: an analysis of elderly patients at our hospital. Nippon Ronen Igakkai Zasshi. 2016;53:143–51.CrossRef
28.
go back to reference Miyazaki Y, Tanaka M, Okamura Y, Kawagoe C. A case of an elderly woman with acute onset type 1 diabetes mellitus that occurred at the age of 85. J Jpn Diabetes Soc. 2003;46:757–61. Miyazaki Y, Tanaka M, Okamura Y, Kawagoe C. A case of an elderly woman with acute onset type 1 diabetes mellitus that occurred at the age of 85. J Jpn Diabetes Soc. 2003;46:757–61.
29.
go back to reference Kawasaki E, Imagawa A, Makino H, Uga M, Abiru N, Hanafusa T, et al. Differences in the contribution of the CTLA4 gene to susceptibility to fulminant and type 1A diabetes in Japanese patients. Diabetes Care. 2008;31:1608–10.CrossRef Kawasaki E, Imagawa A, Makino H, Uga M, Abiru N, Hanafusa T, et al. Differences in the contribution of the CTLA4 gene to susceptibility to fulminant and type 1A diabetes in Japanese patients. Diabetes Care. 2008;31:1608–10.CrossRef
Metadata
Title
Non-autoimmune acute-onset type 1 diabetes mellitus newly developed in an elderly patient presenting elevation of serum pancreatic exocrine enzymes
Authors
Akinori Kanzaki
Morihiro Matsuda
Shinji Yokota
Kenji Takai
Jun Murai
Akihito Otsuka
Hidenori Koyama
Tadashi Nakamura
Publication date
01-01-2022
Publisher
Springer Singapore
Published in
Diabetology International / Issue 1/2022
Print ISSN: 2190-1678
Electronic ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-021-00535-0

Other articles of this Issue 1/2022

Diabetology International 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine